Novartis receives approvable letter for incontinence Drug, Enablex.(New Products)(Brief Article)

Publication: Urologic Nursing

Bookmark this article Print this article Link to this article Email this article Digg It! Add to del.icio.us RSS

COPYRIGHT 2004 Jannetti Publications, Inc.

Novartis Pharmaceuticals Corporation has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Enablex[TM] (darifenacin hydrobromide) for the treatment of overactive bladder. Acquired by Novartis in 2003, Enablex is an M3 selective receptor antagonist (M3 SRA), which works by selectively blocking an important receptor involved...

Read the full article for free courtesy of your local library.